PCDC Data Model

Schema IDhttps://models.d4cg.org/pcdc

Releasepcdc-portal

LicenseCC BY-NC 4.0

Concepts37 classes · 328 slots · 177 enums

Community ·

View

Scope Matrix

Domain	Class	AML	GCT	HL	NBL	NRSTS	RMS
Demographics	ExternalReference
Demographics	FamilyMedicalHistory
Demographics	MedicalHistory
Demographics	OffProtocolTherapyStudy
Demographics	Person
Demographics	Study
Demographics	Subject
Demographics	SurvivalCharacteristic
Demographics	Timing
Disease Attributes	DiseaseCharacteristic
Disease Attributes	Histology
Disease Attributes	LesionCharacteristic
Disease Attributes	MyeloidSarcomaInvolvement
Disease Attributes	Staging
Disease Attributes	TumorAssessment
Intervention	BiopsySurgicalProcedure
Intervention	CellularImmunotherapy
Intervention	NonProtocolTherapy
Intervention	ProtocolTreatmentModifications
Intervention	RadiationTherapy
Intervention	StemCellTransplant
Intervention	TotalDose
Intervention	TransfusionMedicineProcedure
Monitoring	AdverseEvent
Monitoring	GrowingTeratomaSyndrome
Monitoring	LateEffects
Monitoring	MinimalResidualDisease
Monitoring	SecondaryMalignantNeoplasm
Monitoring	SubjectResponse
Testing	Biospecimen
Testing	Cytology
Testing	FunctionTest
Testing	Imaging
Testing	Immunohistochemistry
Testing	Lab
Testing	MolecularAnalysis
Testing	Vital

Rendered Raw

Demographics

Person `1..1`

Diagram

Slot	Range	Slot URI	Description
submitter_id	`string`
subjects_submitter_id	`Subject`
sex		`ncit:C28421`	An arbitrary categorization of individuals based on the assemblage of physical properties related to reproduction, and commonly associated with the designation of such categories as female and male. This designation is based on a combination of observable information from organ inventories, morphological assessments, hormone assessments, genetic testing, observed primary and secondary sex characteristics, menstrual status, and/or obstetric history. Current sex designation may or may not be the same as an individual's sex assigned or reported at birth. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.
race		`ncit:C17049`	A geographic ancestral origin category that is assigned to a population group based mainly on physical characteristics that are thought to be distinct and inherent.
ethnicity		`ncit:C16564`	A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.

Slot Icons:Required

Subject `1..1`

Slot	Range	Slot URI	Description
consortium		`ncit:C61538`	A group formed to undertake a venture that is beyond the capabilities of the individual members. Each member of the consortium brings a high level of expertise in a specific area to ensure the successful completion of the project.
submitter_id	`string`
honest_broker_subject_id	`string`	`ncit:C168949`	Subject identifier assigned by the honest broker.
data_contributor_id		`ncit:C168950`	An identifier assigned to a data contributor.
age_at_censor_status	`integer`
censor_status

Slot Icons:Required

ExternalReference `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
external_links	`string`
external_resource_icon_path	`string`
external_resource_id	`string`
external_resource_name	`string`
external_subject_id	`string`
external_subject_submitter_id	`string`
external_subject_url	`string`

Slot Icons:Required

Study `0..*`

Diagram

Slot	Range	Slot URI	Description
submitter_id	`string`
subjects_submitter_id	`Subject`
age_at_enrollment	`integer`	`ncit:C168843`	Age of subject (in days) when the subject enrolled in the study.
enrolled_status		`ncit:C168928`	The current status of the subject's enrollment.
study_id		`ncit:C83082`	A sequence of characters used to identify, name, or characterize the study.
treatment_arm		`ncit:C15538`	A group of participants in a research study who all receive the same study treatment. (https://mrctcenter.org/glossaryterm/arm/)
year_at_enrollment	`integer`	`ncit:C177353`	The year at which a subject enrolled in a study.
study_phase		`ncit:C48281`	A stage in the clinical research and development of a therapy from first-in-human to post-approval clinical trials.
study_type		`ncit:C142175`	The nature of the investigation for which study information is being collected. (After clinicaltrials.gov)

Slot Icons:Required

Timing `0..*`

Diagram

Slot	Range	Slot URI	Description
submitter_id	`string`
subjects_submitter_id	`Subject`
timing_type
disease_phase		`ncit:C168878`	The stage or period of an individual's disease.
disease_phase_number	`integer`	`ncit:C173258`
age_at_disease_phase	`integer`	`ncit:C168972`
year_at_disease_phase	`integer`	`ncit:C168823`
course		`ncit:C168807`	The type of protocol treatment course administered.
course_number	`integer`	`ncit:C166235`
age_at_course_start	`integer`	`ncit:C168850`
age_at_course_end	`integer`	`ncit:C168851`
age_at_course_anc_500	`integer`	`ncit:C168852`	Age of subject (in days) when their neutrophil count exceeded a threshold of 500 (ANC/mm3) during the course.
cycle_number	`integer`	`ncit:C166208`	The number of the individual chemotherapeutic cycle.
age_at_cycle_start	`integer`	`ncit:C185317`
age_at_cycle_end	`integer`	`ncit:C185316`

Slot Icons:Required

OffProtocolTherapyStudy `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_off	`integer`	`ncit:C172678`
off_type		`ncit:C173256`	The code used to designate that the subject went off therapy or off the study.
reason_off		`ncit:C169005`
another_study		`ncit:C178073`	The subject was enrolled in another therapeutic study after going off the previous study.

Slot Icons:Required

SurvivalCharacteristic `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_lkss	`integer`	`ncit:C168844`	Age of subject (in days) at the last known survival status.
lkss		`ncit:C168931`	The individual's last known survival status.
lkss_with_disease		`ncit:C178074`	The last know survival status of the individual with the disease.
age_lost_to_follow_up	`integer`	`ncit:C172679`	Age of subject (in days) when the subject was lost to follow-up.
cause_of_death		`ncit:C81239`	Cause of death for patient
cause_of_death_other	`string`
TRM_type		`ncit:C173260`	The type of treatment related to the mortality of the subject.
cause_of_death_detail		`ncit:C168868`	Specific details of the cause of death.
cause_of_death_ranking		`ncit:C168932`	Assigning a weighted relevance to the cause of death.

Slot Icons:Required

FamilyMedicalHistory `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
family_history		`ncit:C17726`
relative		`ncit:C21480`	A person related by blood or marriage.
prior_cancer	`string`	`ncit:C185318`

Slot Icons:Required

MedicalHistory `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
medical_history		`ncit:C18772`	A collection of information about a person's health. It may include information about allergies, illnesses and surgeries, and dates and results of physical exams, tests, screenings, and immunizations. It may also include information about medicines taken and about diet and exercise.
medical_history_status
medical_history_category		`ncit:C83018`
assisted_conception

Slot Icons:Required

Testing

Vital `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_vitals	`integer`	`ncit:C168845`
vitals_test		`ncit:C49672`	The act of assessing an individual's current temperature, heart rate, respiratory rate, pulse oxygenation, and blood pressure.
vitals_result	`string`	`ncit:C173522`
vitals_result_numeric	`decimal`	`ncit:C173268`
vitals_result_unit		`ncit:C83161`

Slot Icons:Required

FunctionTest `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at	`integer`	`ncit:C185624`	Age of subject (in days) at the time of the function test.
function_category		`ncit:C185625`	A grouping of items based on their function.
function_result	`string`	`ncit:C162133`
function_test
function_result_numeric	`decimal`	`ncit:C185629`	The result of a function test expressed as a number.
function_result_unit		`ncit:C67415`

Slot Icons:Required

Lab `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_lab	`integer`	`ncit:C172691`	Age of subject (in days) when the laboratory test was performed.
lab_cat		`ncit:C83017`
lab_test		`ncit:C117142`	A character or string that represents the full name of the laboratory assessment.
lab_spec_type		`ncit:C83315`
lab_seq_method		`ncit:C49142`	The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.
lab_result	`string`	`ncit:C36292`	The outcome of a laboratory test.
lab_result_numeric	`decimal`	`ncit:C83320`
lab_result_unit		`ncit:C83106`
lab_method		`ncit:C83312`	A systematic course of action that is performed in order to complete a laboratory test.
traumatic_tap		`ncit:C168879`	Contamination of a cerebrospinal fluid sample by red blood cells greater than 10/mm3.
pmid_ref	`string`	`ncit:C127797`	A globally unique identifier for a biomedical article, as assigned by PubMed.
threshold_high	`decimal`	`ncit:C177365`	The maximum level that must be exceeded for a certain reaction to occur or be manifested.
threshold_low	`decimal`	`ncit:C177366`	The minimum level that must be attained for a certain reaction to occur or be manifested.

Slot Icons:Required

MolecularAnalysis `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_molecular_analysis	`integer`	`ncit:C168848`	Age of subject (in days) when molecular analysis was performed.
molecular_analysis_method		`ncit:C158954`	A request to enter the specific molecular analysis method used to detect abnormalities in the study.
iscn	`string`	`ncit:C173278`
indepen_abb	`decimal`	`ncit:C173279`	The number of independent aberrations found in the karyotype during analysis.
num_metaphases	`decimal`	`ncit:C168918`	The number of cells in metaphase during karyotype analysis.
molecular_abnormality		`ncit:C3910`	A molecular or cytogenetic abnormality which occurs in either human disease states or disease models.
chromosome	`string`	`ncit:C13202`	A structural unit composed of a nucleic acid molecule which controls its own replication through the interaction of specific proteins at one or more origins of replication. [Sequence Ontology: SO:0000340 (SOWiki) http://www.sequenceontology.org/browser/current_svn/term/SO:0000340] EXAMPLE(S): Most humans have 23 pairs of chromosomes--22 pairs of numbered chromosomes, called autosomes, and one pair of sex chromosomes, X and Y. OTHER NAME(S): NOTE(S): This class can represent eukaryotic (e.g. human), mitochondrial, bacterial, and viral chromosomes, for example.
gene1	`string`	`ncit:C173595`	The gene symbol that represents either a single gene that has a mutation or the gene that comprises the 5' portion of the coding sequence involved in a fusion gene mutation.
gene2	`string`	`ncit:C171253`	The gene symbol that represents the gene that comprises the 3' portion of the coding sequence for a fusion gene.
variant_type		`ncit:C97926`
genetic_seq	`string`	`ncit:C97927`
aa_mutation	`string`	`ncit:C97928`	A variation in the sequence of a specific gene product.
molecular_abnormality_result		`ncit:C173596`	An indicator for whether a molecular analysis procedure was performed and whether the assay detected a molecular abnormality.
allelic_ratio	`decimal`	`ncit:C173545`	The determination of the ratio of variant alleles to wild-type alleles present in a sample.
anaplasia
anaplasia_extent
copy_number_status
cytodifferentiation
dna_index
dna_index_numeric	`decimal`
karyotype_status		`ncit:C168871`	The status of the subject's karyotype.
mitoses
num_chromosomes	`decimal`	`ncit:C177370`	The number of chromosomes upon karyotype analysis.

Slot Icons:Required

Biospecimen `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
biospecimen_container_type	`string`
biospecimen_media	`string`
biospecimen_type	`string`
current_qty_unit	`string`
current_qty_value	`string`

Slot Icons:Required

Immunohistochemistry `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_ihc	`integer`	`ncit:C175006`	Age of subject (in days) at immunohistochemistry assessment.
ihc_test		`ncit:C51944`	A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.
ihc_result	`string`	`ncit:C175007`
ihc_result_numeric	`decimal`	`ncit:C177368`

Slot Icons:Required

Cytology `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_cytology	`integer`	`ncit:C177369`
malignant_cells		`ncit:C51944`	A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.
cytology_spec_type		`ncit:C70713`	The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances.

Slot Icons:Required

Imaging `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_imaging	`integer`	`ncit:C185622`
imaging_method		`ncit:C17369`	A method of producing pictures of areas inside the body.
imaging_result		`ncit:C176708`	The result of an evaluation technique using a visual display of structural or functional patterns of organs or tissues that is performed to determine the presence, absence, or degree of a condition.
deauville_score		`ncit:C99723`	A 5 point scale originally devised by Barrington et al. (2014) to assess the response to treatment of lymphoma by FDG-PET scanning, and has since been validated to assess treatment responses in a number of additional solid and non-solid tumors.
qpet_score	`decimal`	`ncit:C185623`	A methodology that provides semi-automatic quantification for interim FDG-PET response in lymphoma. It extends the ordinal Deauville score to a continuous scale.

Slot Icons:Required

Disease_Attributes

Histology `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_hist_assessment	`integer`	`ncit:C175004`	Age of subject (in days) at histology assessment.
hist_assessment_review		`ncit:C177360`
histology		`ncit:C16681`
histology_result	`string`	`ncit:C166246`
histology_result_numeric	`decimal`	`ncit:C177361`
histology_result_unit		`ncit:C177362`
hist_ICD_O_morph_code	`string`	`ncit:C176985`
histology_grade		`ncit:C18000`	A description of a tumor based on how abnormal the cancer cells look under a microscope and how quickly the tumor is likely to grow and spread. Grading systems are different for each type of cancer.
mature_glial_implants		`ncit:C177363`	A nodule of mature glial tissue that develops in the peritoneum. It is usually accompanied by mature or immature ovarian teratoma.
somatic_malignancy_type		`ncit:C177364`	A malignant non-germ cell component that typically develops secondarily within a germ cell tumor. The malignant cellular component is usually sarcomatous or carcinomatous.
histology_inpc

Slot Icons:Required

Staging `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_staging	`integer`	`ncit:C177359`	Age of subject (in days) at the time of the staging assessment.
AB		`ncit:C181839`	An indication whether A- or B-designations, based on the Ann Arbor lymphoma classification system guidelines, were used to modify staging classifications.
E		`ncit:C177586`	An indication of whether a record includes data regarding extranodal involvement based on the Ann Arbor lymphoma classification system guidelines.
S		`ncit:C185484`	An indication of whether a record includes data regarding splenic involvement based on the Ann Arbor lymphoma classification system guidelines.
stage_system		`ncit:C18004`	A systematic method for clinicopathologic evaluation of tumors.
stage		`ncit:C16899`	The extent of a cancer in the body.
irs_group
tnm_finding

Slot Icons:Required

DiseaseCharacteristic `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
fab_type		`ncit:C91220`
who_aml		`ncit:C159157`
disease_site		`ncit:C173263`
detection_method		`ncit:C173262`	The method used to detect the extent of the disease involvement.
CNS_disease_status		`ncit:C173264`
MPAL		`ncit:C82179`	An acute leukemia of ambiguous lineage. It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.
MLDS		`ncit:C43223`	Acute myeloid leukemia occurring in children with Down syndrome. During the first 3 years of life, it is usually the megakaryoblastic subtype, and is associated with GATA1 gene mutation. After age 4 this is no longer the case.
TAMDS		`ncit:C82339`	A myeloid proliferation occurring in newborns with Down syndrome. It is clinically and morphologically indistinguishable from acute myeloid leukemia and is associated with GATA1 mutations. The blasts display morphologic and immunophenotypic features of megakaryocytic lineage. In the majority of patients the myeloid proliferation undergoes spontaneous remission.
secondary_AML		`ncit:C25765`	An acute myeloid leukemia arising from prior myelodysplastic syndrome, myeloproliferative neoplasm, or myelodysplastic/myeloproliferative neoplasm, or as a result of previous exposure to alkylating agents or topoisomerase II inhibitors.
bulky_nodal_aggregate
BULK_MED_MASS		`ncit:C178075`	When the maximum width of a mass is equal or greater than one-third of the internal transverse diameter of the thorax at the level of T5/6 on a PA CXR. Bulk at an alternate site is defined as any mass measuring 10 cm or more by any imaging study.
bulk_disease		`ncit:C38655`	The presence of a large mass or matted lymph nodes in an imaging study. This term almost always refers to lymphomas and its definition depends on the histological type of lymphoma. Generally, a tumor mass measuring more than 7 cm or more than 10 cm in diameter is considered bulky disease.
fever		`ncit:C3038`	A disorder characterized by elevation of the body's temperature above the upper limit of normal.
igccc_risk_group		`ncit:C111073`
initial_treatment_category
karnofsky		`ncit:C28013`
lansky		`ncit:C38144`
magic_risk_group		`ncit:C177316`
med_ratio	`decimal`	`ncit:C185323`	A measurement of the width of the mediastinum divided by the width of the chest.
mki
night_sweats		`ncit:C3279`	Nocturnal perspiration that is unrelated to environmental temperature.
nodular_splenic		`ncit:C185322`	A finding indicating that Hodgkin lymphoma has spread to the spleen focally and there is associated involvement of the hilar lymph nodes.
weight_loss		`ncit:C3445`
histology_inpc

Slot Icons:Required

MyeloidSarcomaInvolvement `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
myeloid_sarcoma		`ncit:C3520`	A malignant neoplasm composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone.
myeloid_sarcoma_site		`ncit:C168822`

Slot Icons:Required

TumorAssessment `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_tumor_assessment	`integer`	`ncit:C174997`	Age of subject (in days) at tumor assessment.
necrosis
necrosis_pct	`decimal`
nodal_site
tumor_detection_method		`ncit:C117438`
tumor_classification		`ncit:C174459`	The classification of a tumor based primarily on histopathological characteristics.
tumor_site		`ncit:C157120`	The anatomic site of the tumor.
tumor_laterality		`ncit:C119931`
tumor_state
nodal_involvement
depth
invasiveness
longest_diam_dim1	`decimal`	`ncit:C96684`	The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.
longest_diam_dim2	`decimal`	`ncit:C96684`	The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.
longest_diam_dim3	`decimal`	`ncit:C96684`	The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.
nodal_clinical
nodal_pathology
parameningeal_extension
pleural_effusion		`ncit:C3331`	A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.
tumor_site_other	`string`
tumor_size

Slot Icons:Required

LesionCharacteristic `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_lesion_assessment	`integer`	`ncit:C185485`
lesion_assessment_review		`ncit:C185324`	The institution which has reviewed the lesion assessment.
lesion_detection_method		`ncit:C173262`	The method used to detect the extent of the disease involvement.
lesion_classification		`ncit:C185489`
lesion_site		`ncit:C166232`	Specifies the anatomic site of a localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.
e_extension_site		`ncit:C185478`
lesion_laterality		`ncit:C185479`
lesion_bulky		`ncit:C185477`
longest_diam_dim1	`decimal`	`ncit:C96684`	The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.
diam_dim1_type		`ncit:C185494`
longest_diam_dim2	`decimal`	`ncit:C96684`	The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.
diam_dim2_type		`ncit:C185495`
longest_diam_dim3	`decimal`	`ncit:C96684`	The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference.
diam_dim3_type		`ncit:C185496`
pleural_effusion		`ncit:C3331`	A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.
pericardial_effusion		`ncit:C3319`	A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.
lesion_response		`ncit:C94534`	A qualitative or quantitative measurement of the response of a target lesion(s) to the therapy.
lesion_pct_change	`decimal`	`ncit:C185497`	The percentage of change in a particular lesion.

Slot Icons:Required

Intervention

BiopsySurgicalProcedure `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_procedure	`integer`	`ncit:C175008`	Age of subject (in days) at procedure.
procedure_performed
procedure_treatment_timing
procedure_site		`ncit:C164323`
procedure_laterality
procedure_type		`ncit:C161601`	A categorization of surgical procedures by type or purpose.
procedure_extent		`ncit:C157443`	A description of the relative amount of tissue, blood vessel, or organ that has been removed.
mass_present
viable_tumor_specimen
viable_tumor_margin
margins		`ncit:C41227`	One of the criteria for assessment of the effectiveness of given surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. It is defined by the tissue plane through which the dissection has been done and the actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient. There are four types of surgical margins: intracapsular or intralesional, marginal, wide, and radical.
tumor_classification		`ncit:C174459`	The classification of a tumor based primarily on histopathological characteristics.

Slot Icons:Required

StemCellTransplant `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_sct	`integer`	`ncit:C168853`	Age of subject (in days) at the time of stem cell transplantation.
sct_type		`ncit:C168864`	Type of stem-cell transplantation the subject received.
sct_source		`ncit:C168870`	The source of the stem cells for the stem cell transplant.
sct_donor_relationship		`ncit:C168869`	The biological relationship between the stem cell donor and the recipients.
hla_match		`ncit:C169009`	A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles so that transplant materials can be transferred into a patient with the same or similar profile.
number_hla	`decimal`	`ncit:C173301`	The number of human leukocyte antigens that were evaluated.
number_matches	`decimal`	`ncit:C173302`	The number of human leukocyte antigens that matched between the donor and the recipient.
hla_a_result		`ncit:C168923`	The extent of HLA-A matching between the donor and the recipient.
hla_b_result		`ncit:C168924`	The extent of HLA-B matching between the donor and the recipient.
hla_c_result		`ncit:C168925`	The extent of HLA-C matching between the donor and the recipient.
hla_drb1_result		`ncit:C168926`	The extent of HLA-DRB1 matching between the donor and the recipient.
hla_dq_result		`ncit:C168927`	The extent of HLA-DQ matching between the donor and the recipient.
sct_conditioning_type		`ncit:C169014`	Type of conditioning the subject received prior to stem-cell transplantation.
sct_tbi		`ncit:C15350`	A procedure involving irradiation of the whole body.
sct_cd34_coll	`decimal`	`ncit:C175036`	The determination of the amount of CD34 expressing stem cells present in a sample.

Slot Icons:Required

TransfusionMedicineProcedure `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_tmp_start	`integer`	`ncit:C172697`	Age of subject (in days) at the start of the transfusion procedure.
tmp_type		`ncit:C173057`	An infusion or replacement of blood components.
tmp_product		`ncit:C173287`	The type of product intended for transfusion.
tmp_product_type		`ncit:C185655`	The type of processing that is used on the transfusion product.
tmp_number_units	`decimal`	`ncit:C185656`	The number of units transfused into an individual.

Slot Icons:Required

RadiationTherapy `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_rt_start	`integer`	`ncit:C172695`	Age of subject (in days) at the start of radiation therapy.
age_at_rt_end	`integer`	`ncit:C172696`	Age of subject (in days) at the end of radiation therapy.
rt_timing
administration_status
rt_site		`ncit:C173281`	The anatomic site of the radiation therapy.
rt_dose	`decimal`	`ncit:C173282`	The total radiation dose administered.
rt_unit		`ncit:C18068`	A unit of measurement of the dose of radiation received or absorbed.
boost_dose	`decimal`	`ncit:C185679`	The dose amount of the radiation boost.
boost		`ncit:C137812`	One or more extra radiation treatments targeted at the tumor bed, given after the regular sessions of radiation are complete.
energy_type		`ncit:C15313`	Patient required additional radiation therapy.
num_fraction	`decimal`	`ncit:C175034`	The number of divided radiation doses received per day.
rt_laterality		`ncit:C175523`
tumor_classification		`ncit:C174459`	The classification of a tumor based primarily on histopathological characteristics.

Slot Icons:Required

TotalDose `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_total_dose_start	`integer`	`ncit:C172698`	Age of subject (in days) at the start of the total dose calculation.
age_at_total_dose_end	`integer`	`ncit:C172686`	Age of subject (in days) at the end of the total dose calculation.
cycle_number	`integer`	`ncit:C166208`	The number of the individual chemotherapeutic cycle.
administration_status
route		`ncit:C38114`
antineoplastic_agent		`ncit:C274`	A drug used to treat cancer.
number_doses	`decimal`	`ncit:C173293`	The total number of doses administered to the patient over the defined period of time.
total_dose_administered	`decimal`	`ncit:C94394`	In medicine, the total amount of a drug or radiation given to a patient over time; for example, the total dose of radiation given in a series of radiation treatments.
total_dose_intended	`decimal`	`ncit:C173294`	The total amount of the medication intended to be administered to the patient over the defined period of time.
total_dose_units		`ncit:C173295`
route_detail		`ncit:C38114`

Slot Icons:Required

ProtocolTreatmentModifications `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_mod	`integer`	`ncit:C185630`
mod_type		`ncit:C185632`	The kind of modification.
mod_rationale		`ncit:C185636`	The rationale for why an entity or event is changed.
mod_reason		`ncit:C93529`	The rationale for why an entity or event is changed.
toxicity_detail		`ncit:C185693`	Information about the conditions surrounding the toxicity.
toxicity_immune		`ncit:C63814`	Toxicity that impairs or damages the immune system.
toxicity_infusion		`ncit:C185649`	Toxicity related to an infusion.
original_agent		`ncit:C185650`	The first agent planned for a therapy.
sub_agent		`ncit:C185634`	A medication was substituted with another.

Slot Icons:Required

CellularImmunotherapy `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_cimt_start	`integer`	`ncit:C173195`	Age of subject (in days) at the start of the cellular immunotherapy.
cimt_type		`ncit:C173289`

Slot Icons:Required

NonProtocolTherapy `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
npt_timing		`ncit:C175038`	A description of the timing of when the non-protocol therapy was received.
npt_type		`ncit:C175041`
npt_sct_type		`ncit:C186477`

Slot Icons:Required

Monitoring

SubjectResponse `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_response	`integer`	`ncit:C168856`	Age of subject (in days) when the response assessment was made.
response_method		`ncit:C178148`	The method used to assess the response to therapy.
response_category		`ncit:C173306`	The category used to assess the response to therapy.
response_criteria
response_criteria_version	`string`
response		`ncit:C50995`	Status of the disease treated with radiation therapy at the time of the record.
bm_pct_blasts_at_response	`decimal`	`ncit:C168959`	The percent of cells that were blasts in the subject's bone marrow used to make the response assessment.
bm_analysis_method_at_response		`ncit:C168960`	The modality used to determine the bone marrow percent blasts.
anc_at_response	`decimal`	`ncit:C168961`	The absolute neutrophil count used to make the response assessment.
anc_threshold_at_response		`ncit:C168962`	Subject exceeded an absolute neutrophil count threshold of >= 500 (ANC/mm3) at the time of the response assessment.
platelet_count_at_response	`decimal`	`ncit:C168963`	The platelet count used to make the response assessment.
platelet_threshold_at_response		`ncit:C168964`	Subject exceeded a platelet count threshold of >=50,000 (platelets/mm3) at the time of the response assessment.
interim_response		`ncit:C185657`	An evaluation prior to the completion of therapy that the individual is responding to therapy.
necrosis
necrosis_pct	`decimal`
nodular_splenic		`ncit:C185322`	A finding indicating that Hodgkin lymphoma has spread to the spleen focally and there is associated involvement of the hilar lymph nodes.
palpable_nodes		`ncit:C185660`	The lymph nodes are felt on palpation.
symptoms		`ncit:C25269`	Exhibiting the symptoms of a particular disease.
tx_prior_response

Slot Icons:Required

MinimalResidualDisease `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_mrd_assessment	`integer`	`ncit:C168855`	Age of subject (in days) at assessment of minimal residual disease.
mrd_method		`ncit:C168933`	Modality used to determine minimal residual disease.
flow_cytometry_type		`ncit:C173732`
mrd_result	`string`	`ncit:C124433`
mrd_result_numeric	`decimal`	`ncit:C168951`
mrd_result_unit		`ncit:C173304`
mrd_sensitivity	`decimal`	`ncit:C168957`	Sensitivity of modality used to determine minimal residual disease.
mrd_sample_source		`ncit:C168958`	Source of sample used for minimal residual disease assessment.
mrd_molecular_markers		`ncit:C168895`	A one or more molecular characteristics that are used as a biomarker for minimal residual disease.

Slot Icons:Required

SecondaryMalignantNeoplasm `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_smn	`integer`	`ncit:C168860`	Age of subject (in days) at the diagnosis of the secondary malignant neoplasm.
smn_morph_sno	`string`
smn_morph_txt	`string`
smn_site
smn_top_sno	`string`
smn_top_txt	`string`
smn_type
smn_yn
smn_morph_icdo	`string`	`ncit:C168862`
smn_top_icdo	`string`	`ncit:C168863`
smn_field		`ncit:C175044`	The location of the second malignant neoplasm related to the prior radiation field.

Slot Icons:Required

AdverseEvent `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_ae	`integer`	`ncit:C172677`	Age of subject (in days) at the onset of the adverse event.
age_at_ae_resolved	`enum`	`ncit:C175043`	Age of subject (in days) at adverse event resolution.
adverse_event		`ncit:C41331`	An unexpected medical problem that happens during treatment with a drug or other therapy. Adverse effects do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe.
ae_code	`string`	`ncit:C173313`	The code of the adverse event.
ae_system		`ncit:C168872`	The name of the system used to grade the adverse events.
ae_system_version	`string`	`ncit:C173314`	The version of the adverse event grading system.
ae_grade		`ncit:C166200`	A numeric value corresponding to the degree of severity of an adverse event.
ae_attribution		`ncit:C41358`	A specific identifiable level (defined qualitatively or quantitatively) of probability of adverse event being caused or associated with the product or procedure administration to a patient.
ae_outcome		`ncit:C49489`	A condition or event that is attributed to the adverse event and is the result or conclusion of the adverse event.
ae_icu		`ncit:C173316`	An indication of whether the subject was admitted to the intensive care unit.
ae_medication		`ncit:C173317`	The medication related to the adverse event.
ae_intervention		`ncit:C173318`	An intervention was administered to treat the adverse event.
ae_med_intervention_detail		`ncit:C173319`	The intervention or medication detail of the adverse event.
ae_pathogen		`ncit:C185665`	The pathogen identified as the agent causing the adverse event.
ae_pathogen_confirmation		`ncit:C168955`	An indication that the reported pathogen was confirmed or suspected as the cause of an infection.
gvhd_acuity		`ncit:C168861`	The assessed level of seriousness assigned to the graft versus host disease.
gvhd_organ		`ncit:C168883`	The organs involved in the graft vs host disease.

Slot Icons:Required

GrowingTeratomaSyndrome `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
timings_submitter_id	`Timing`
age_at_gts	`integer`	`ncit:C177375`
gts_treatment		`ncit:C177376`	The therapy chosen to treat Growing Teratoma Syndrome.

Slot Icons:Required

LateEffects `0..*`

Diagram

Slot	Range	Slot URI	Description
subjects_submitter_id	`Subject`
age_at_le_eval	`integer`	`ncit:C185670`	Age of subject (in days) when the late effect evaluation was performed.
le		`ncit:C4808`	Any symptom or condition which is a result of a medical intervention but arises months or years after it.
le_detail		`ncit:C185686`	An in-depth explanation of a health problem that occurs months or years after a disease is diagnosed or after treatment has ended.
le_sub_detail		`ncit:C186352`	An added in-depth or explanation of a health problem that occurs months or years after a disease is diagnosed or after treatment has ended.
le_severity_grade		`ncit:C186476`	A severity grade assigned to the late effects.
le_ctcae_version	`string`	`ncit:C185691`	The version of the Common Terminology Criteria for Adverse Events (CTCAE) Terminology.

Permissible Value	Meaning	Description
Ann Arbor A Symptoms Indicator	`ncit:C185483`	An indication of whether a record includes A-symptom data based on the Ann Arbor lymphoma classification system guidelines.
Ann Arbor B Symptoms Indicator	`ncit:C177585`	An indication of whether a record includes B-symptom data based on the Ann Arbor lymphoma classification system guidelines.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Administered
Medication Administered
Medication Not Administered
Not Administered
Unknown

Permissible Value	Meaning	Description
Allergic Reaction	`ncit:C114476`	A disorder characterized by an adverse local or general response from exposure to an allergen.
Cardiac Toxicity	`ncit:C27994`	Toxicity that affects the heart.
Endocrine Toxicity	`ncit:C138163`	Indicates that a toxicity adverse effect has been experienced during endocrine drug treatment.
Fatigue	`ncit:C3036`	A condition marked by extreme tiredness and inability to function due lack of energy. Fatigue may be acute or chronic.
GI Toxicity	`ncit:C185646`	Toxicity that impairs or damages the gastrointestinal system.
Graft Versus Host Disease	`ncit:C3063`	A disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes.
Hemorrhage	`ncit:C26791`	In medicine, loss of blood from damaged blood vessels. A hemorrhage may be internal or external, and usually involves a lot of bleeding in a short time.
Hepatic Toxicity	`ncit:C185645`	Toxicity that impairs or damages the liver.
Hyperbilirubinemia	`ncit:C27088`	A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.
Infection	`ncit:C128320`	The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.
Left Ventricular Systolic Dysfunction	`ncit:C64251`	A disorder characterized by failure of the left ventricle to produce adequate output despite an increase in distending pressure and in end-diastolic volume. Clinical manifestations may include dyspnea, orthopnea, and other signs and symptoms of pulmonary congestion and edema.
Mucositis	`ncit:C115965`	Inflammation of the mucous membranes.
Multi Organ Failure	`ncit:C75568`	Complete impairment of two or more organs or organ systems.
Musculoskeletal Toxicity	`ncit:C185647`	A toxicity that impairs or damages the musculoskeletal system.
Neuropathy	`ncit:C4731`	A disorder affecting the cranial nerves or the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness.
Neurotoxicity Syndrome	`ncit:C27961`	A group of neurologic disorders caused by damage to the nervous system following exposure to pharmacologic, biologic, and chemical agents. Examples of neurotoxins include chemotherapy agents, radiation treatment, heavy metals, pesticides, and food additives.
Neutropenia	`ncit:C80520`	A condition in which there is a lower-than-normal number of neutrophils (a type of white blood cell).
Ototoxicity	`ncit:C66929`	Damage to the inner ear as a result of exposure to drugs or chemicals.
Psychiatric Toxicity	`ncit:C185648`	Toxicity that develops due to the administration of psychiatric medications.
Pulmonary Toxicity	`ncit:C177374`	Toxicity that impairs or damages the lung(s). This condition is often caused by the administration of a pharmaceutical agent that causes damage to the lungs.
Rashes	`ncit:C39594`	An eruption in the skin which affects its appearance and/or texture.
Renal Toxicity	`ncit:C115459`	Toxicity that impairs or damages the kidney. This condition is often caused by the administration of a pharmaceutical agent that causes damage to the kidney.
Sinusoidal Obstruction Syndrome	`ncit:C26793`	A condition in which some of the veins in the liver are blocked. It is sometimes a complication of high-dose chemotherapy given before a bone marrow transplant and is marked by increases in weight, liver size, and blood levels of bilirubin.
Thrombocytopenia	`ncit:C3408`	A condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.
Typhlitis	`ncit:C38043`	A disorder characterized by inflammation of the cecum.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Definite	`ncit:C53260`	A characteristic used to qualify the adverse event as certainly related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to medical intervention, and which cannot be explained by concurrent disease or other interventions. The response to withdrawal of the medical product (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary.
Possible	`ncit:C53258`	A characteristic indicating that an adverse event may be related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear.
Probable	`ncit:C41357`	Probable adverse event relationship to study product or procedure is defined when there is a clear-cut temporal association between product or procedure administration and adverse event, and a potential alternative etiology of the event is not apparent.
Unlikely	`ncit:C53257`	A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations.
Unrelated	`ncit:C53256`	A characteristic used to qualify the adverse event as clearly not related to the medical intervention.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Expected	`ncit:C41333`	Any adverse event associated with a medical product or procedure, whose nature and severity have been previously observed, identified in nature, severity, or frequency, and documented in the investigator brochure, investigational plan, protocol, current consent form, scientific publication, or in other relevant and reliable document. The old term Side Effect is retired and should not be used.
Unexpected	`ncit:C41334`	An adverse reaction, whose nature, severity, specificity, or outcome is not consistent with the term or description used in the applicable product information. [ICH E2] See also adverse drug reaction.

Permissible Value	Meaning	Description
Grade 1	`ncit:C41338`	A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.
Grade 2	`ncit:C41339`	A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant.
Grade 3	`ncit:C41340`	A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.
Grade 4	`ncit:C41337`	An adverse event, and/or its immediate sequelae, which is associated with an imminent risk of death or which is associated with physical or mental disabilities that affect or limit the ability of a person to perform activities of daily living (eating, ambulation, toileting, etc.) See NCI Common Terminology Criteria for Adverse Events.
Grade 5	`ncit:C48275`	The termination of life as a result of an adverse event. (NCI)
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
ACE-Inhibitor	`ncit:C247`	A drug that is used to lower blood pressure. An ACE inhibitor is a type of antihypertensive agent.
Heart Transplant	`ncit:C15246`	A surgical procedure in which a damaged heart is removed and replaced by another heart from a suitable donor.
Inotropic Support	`ncit:C168966`	An agent used to modify the strength of the contraction of the heart muscle.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Death, Contributory	`ncit:C168948`	Any adverse event contributing to the cause of death.
Death, Noncontributory	`ncit:C173315`	The adverse event did not directly contribute to the death of the subject.
Not Recovered	`ncit:C49494`	One of the possible results of an adverse event outcome that indicates that the event has not improved or recuperated.
Not Yet Recovered	`ncit:C49494`	One of the possible results of an adverse event outcome that indicates that the event has not improved or recuperated.
Recovered	`ncit:C85257`
Recovered With Sequelae	`ncit:C49495`	One of the possible results of an adverse event outcome where the subject recuperated but retained pathological conditions resulting from the prior disease or injury.
Recovered with Sequelae	`ncit:C49495`	One of the possible results of an adverse event outcome where the subject recuperated but retained pathological conditions resulting from the prior disease or injury.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Confirmed	`ncit:C25458`	Having been established or verified.
Suspected	`ncit:C71458`	Believed likely.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Bacteria	`ncit:C14187`	A large group of single-cell microorganisms. Some cause infections and disease in animals and humans. The singular of bacteria is bacterium.
Fungus	`ncit:C14209`	A eukaryotic, heterotrophic organism that lives as a saprobe or parasite, and includes yeasts and molds. It reproduces either sexually or asexually, and has a life cycle that ranges from simple to complex.
Virus	`ncit:C14283`	An infectious agent that comprises two parts: genetic material and a protein coat. These organisms lack independent metabolism, and they must infect the cells of other types of organisms to reproduce.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Balis Neuropathy Scale	`ncit:C178081`	An instrument used to grade neurotoxicity occurring in children on a 0-4 scale, where the higher number indicates worse neuropathy.
CTCAE	`ncit:C49704`	A standard terminology developed and maintained by the National Cancer Institute to report adverse events occurring in cancer clinical trials. The CTCAE contains a grading scale for each adverse event term representing the severity of the event. (NCI)
European Society for Blood and Marrow Transplantation (EBMT)	`ncit:C168842`	A non-profit organization established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantations to share experiences and develop co-operative studies.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
In Vitro Fertilization	`ncit:C16580`	A procedure in which eggs are removed from a woman's ovary and combined with sperm outside the body to form embryos. The embryos are grown in the laboratory for several days and then either placed in a woman's uterus or cryopreserved (frozen) for future use.
Intracytoplasmic Sperm Injection	`ncit:C185482`	Injecting a single sperm into the center of an egg.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Core Needle Biopsy	`ncit:C15680`
Incisional Biopsy	`ncit:C15386`	A procedure in which a surgical incision (cut) is made through the skin to expose and remove tissues. The biopsy tissue is examined under a microscope by a pathologist. An open biopsy may be done in the doctor's office or in the hospital, and may use local anesthesia or general anesthesia. A lumpectomy to remove a breast tumor is a type of open biopsy.
Other	`ncit:C17649`	A proper value is applicable but not known.

Permissible Value	Meaning	Description
Flow Cytometry	`ncit:C16585`	A method of measuring the number of cells in a sample, the percentage of live cells in a sample, and certain characteristics of cells, such as size, shape, and the presence of tumor markers on the cell surface. The cells are stained with a light-sensitive dye, placed in a fluid, and passed in a stream before a laser or other type of light. The measurements are based on how the light-sensitive dye reacts to the light.
Morphology	`ncit:C35867`	A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Acute Respiratory Distress Syndrome
Bacterial Infection	`ncit:C2890`	An acute infectious disorder caused by gram positive or gram negative bacteria.
Cardiac Disease	`ncit:C3079`	A non-neoplastic or neoplastic disorder that affects the heart and/or the pericardium. Representative examples include endocarditis, pericarditis, atrial myxoma, cardiac myeloid sarcoma, and pericardial malignant mesothelioma.
Cardiac Failure	`ncit:C50577`	A clinical condition in which the function of the heart is inadequate to meet the metabolic needs of the body.
Fungal Infection	`ncit:C3245`	An infection caused by a fungus.
Graft Versus Host Disease	`ncit:C3063`	A disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes.
Hemorrhage	`ncit:C26791`	In medicine, loss of blood from damaged blood vessels. A hemorrhage may be internal or external, and usually involves a lot of bleeding in a short time.
Infection, NOS	`ncit:C128320`	The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.
Multi Organ Failure
Organ Failure, NOS	`ncit:C185320`	The failure of an essential system in the body.
Pulmonary Disease	`ncit:C3198`	A non-neoplastic or neoplastic disorder affecting the lung. Representative examples of non-neoplastic disorders include chronic obstructive pulmonary disease and pneumonia. Representative examples of neoplastic disorders include benign processes (e.g., respiratory papilloma) and malignant processes (e.g., lung carcinoma and metastatic cancer to the lung).
Sinusoidal Obstruction Syndrome	`ncit:C26793`	A condition in which some of the veins in the liver are blocked. It is sometimes a complication of high-dose chemotherapy given before a bone marrow transplant and is marked by increases in weight, liver size, and blood levels of bilirubin.
Surgical Complication	`ncit:C164157`	A disease or disorder that occurs during, soon after or as a result of a surgical procedure.
Unacceptable Toxicity
Viral Infection	`ncit:C3439`	Any disease caused by a virus.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Disease Progression	`ncit:C168970`	An indication that the subject has died due to the progression of their disease.
Post-Treatment Disease Complications	`ncit:C168877`	A complication of the disease that occurred after treatment.
Pre-Treatment Disease Complications	`ncit:C168876`	A complication of the disease that existed prior to treatment.
Secondary Malignancy	`ncit:C4968`	A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.
Treatment-Related Mortality	`ncit:C166165`	A death that is considered to be causally linked to a treatment.
Treatment-Related mortality	`ncit:C166165`	A death that is considered to be causally linked to a treatment.
Unrelated to Disease or Treatment	`ncit:C17649`	A proper value is applicable but not known.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Contributory	`ncit:C168948`	Any adverse event contributing to the cause of death.
Primary	`ncit:C99531`	The first significant event which ultimately led to death.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Subject has had one or more events
Subject is censored (i.e. has had no events(s))
Unknown
Not Reported

Permissible Value	Meaning	Description
Chimeric Antigen Receptor T-cell Therapy	`ncit:C126102`	A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. Chimeric antigen receptor T-cell therapy is being studied in the treatment of some types of cancer.
Donor Lymphocyte Infusion	`ncit:C16145`	A type of therapy in which lymphocytes from the blood of a donor are given to a patient who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Donor lymphocyte infusion is used to treat chronic myelogenous leukemia (CML) that has come back and myeloma. It is being studied in the treatment of other types of cancer.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
CNS1	`ncit:C116833`	Central nervous system status defined as puncture nontraumatic without leukemic blasts after cytocentrifugation. (Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan;14(1):18-24.)
CNS2	`ncit:C116834`	Central nervous system status defined as puncture nontraumatic with less than or equal to 5 WBC/uL in cerebral spinal fluid with identifiable blasts.(Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan;14(1):18-24.)
CNS3	`ncit:C116835`	Central nervous system status defined as puncture nontraumatic with greater than 5 WBC/uL in cerebral spinal fluid with identifiable blasts. (Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan;14(1):18-24.)
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
INRG	`ncit:C192760`
INSTRuCT	`ncit:C192758`
INTERACT	`ncit:C192762`	A consortium launched in 2021 as a collaboration between acute myeloid leukemia researchers from Children's Oncology Group, European Pediatric Acute Leukemia, Japan Children's Cancer Group, and St. Jude Children's Research Hospital. To date, INTERACT has identified 18 studies from 10 clinical trials research groups that can be contributed to the data commons, and its statisticians are actively working to harmonize clinical data from more than 6,000 individuals who have had pediatric cancer.
MaGIC	`ncit:C192759`	A global consortium of pediatric oncologists, gynecologic oncologists, testicular cancer specialists, surgeons, pathologists, epidemiologists, statisticians, bioinformaticists, and biomedical scientists with the shared goal of developing more effective treatments for germ cell tumors through scientific inquiry.
NODAL	`ncit:C192761`

Permissible Value	Meaning	Description
Chemoimmunotherapy	`ncit:C94251`	Chemotherapy combined with immunotherapy. Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer.
Chemotherapy	`ncit:C15632`	Non-systemic chemotherapy treatment (e.g., intra-peritoneal, intra-cavitary, intra-thecal), or chemotherapy not described by Chemotherapy Single Agent Systemic or Multi-Agent Systemic.
Consolidation	`ncit:C15679`	Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells.
Immunotherapy	`ncit:C15262`	A therapy designed to induce changes in a patient's immune status.
Induction	`ncit:C158876`	The first choice of treatment for a particular type of cancer.
Intensification	`ncit:C173105`	A second round of intense chemotherapy that is higher than the first.
Maintenance	`ncit:C15688`	Continuation of treatment for an extended period of time to prevent relapse.
Palliative Treatment	`ncit:C15292`	The patient- and family-centered active holistic care of patients with advanced, progressive disease. Essential components of palliative care are: pain and symptom control, communication regarding treatment and alternatives, prognosis, and available services, rehabilitation services, care that addresses treatment and palliative concerns, intellectual, emotional, social, and spiritual needs, terminal care, support in bereavement. The goal of palliative care is an achievement of the best quality of life for patients and their families.
Prephase	`ncit:C168826`	A chemotherapy treatment administered prior to the definitive chemotherapy treatment.
Radiation Therapy	`ncit:C15313`	Patient required additional radiation therapy.
Stem Cell Transplant Conditioning	`ncit:C168794`	A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).
Other	`ncit:C17649`	A proper value is applicable but not known.

Permissible Value	Meaning	Description
Cerebrospinal Fluid	`ncit:C12692`	A clear, colorless, bodily fluid, that occupies the subarachnoid space and the ventricular system around and inside the brain and spinal cord.
Peritoneal Fluid	`ncit:C77612`
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
AIEOP	`ncit:C168887`	A group from Bologna, Italy, comprised mainly of pediatricians, hematologists, oncologists, surgeons, biologists, nurses and psychologists who are devoted to addressing the problems of hematology, oncology and immunology in the child and adolescent.
BFM-SG	`ncit:C168888`	A study group formed in 1975 by three individuals, Hansjorg Riehm in Berlin (B), Bernhard Kornhuber in Frankfurt (F) and Gunther Schellong in Munster (M), who initiated the first multicenter BFM trial. The BFM treatment concept was based on an intensive chemotherapeutic approach employing eight different drugs which led to a revolutionary increase in the survival of children and adolescents with acute lymphoblastic leukemia.
CCLG	`ncit:C177327`	A children's cancer charity and United Kingdom and Ireland's professional association for those involved in the treatment and care of children with cancer.
COG	`ncit:C39353`	An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.
DCOG	`ncit:C168889`	A collaborating partner in Innovative Therapies for Children with Cancer Consortium (ITCC), a European based consortium to promote the clinical evaluation of new anti-cancer compounds in children with cancer.
DFCI	`ncit:C177330`	An institute founded in 1947 in Boston, Massachusetts, committed to providing treatment for adults and children with cancer, and developing cures with cutting-edge research.
GPLP
GPOH
JACLS	`ncit:C168890`	A study group in Japan investigating childhood leukemia.
JCCG
JPLSG	`ncit:C168891`	A study group in Japan investigating pediatric leukemia and lymphoma.
MRC	`ncit:C168892`	A publicly funded organization that is part of United Kingdom Research and Innovation, and is dedicated to improving human health through world-class medical research.
NOPHO	`ncit:C168893`	A collaborative group formed in 1984 with members from Denmark, Finland, Iceland, Lithuania, Norway and Sweden and whose goal was to secure that all Nordic children suffering from leukemia would receive optimal therapy wherever they lived.
NRG-Oncology	`ncit:C177331`	A leading protocol organization within the National Clinical Trials Network that seeks to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research.
PPLLSG	`ncit:C168894`	A collaborative group established in 1974 that had the original goal of implementing unified protocols with standardized diagnostic criteria and therapy regimens for Hodgkin's disease and acute lymphoblastic leukemia. The prospects were widened to include non-Hodgkin's lymphomas and acute myelogenous leukemia in 1983.
SFCE	`ncit:C177328`	An association founded in France in 2003 which promotes the organization of care and scientific research in the field of childhood and adolescent cancer.
SIOPEN
SJCRH	`ncit:C39510`	The St. Jude Children's Research Hospital received its NCI designation in 1977 and was awarded status as a comprehensive cancer center by NCI in 2008. Research is focused specifically on childhood cancers, acquired and inherited immunodeficiencies and genetic disorders.
SOPOBE	`ncit:C177329`	A society founded in 1981 committed to improve the prognosis of children and adolescents with cancer.

Permissible Value	Meaning	Description
Score 1	`ncit:C99728`	No uptake. (Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048-58.)
Score 2	`ncit:C99747`	The results of the positron emission tomography are negative; the tracer uptake is less than or equal to the mediastinum.
Score 3	`ncit:C99748`	The results of the positron emission tomography are negative; the tracer uptake is greater than the mediastinum but less than or equal to the liver.
Score 4	`ncit:C99749`	The results of the positron emission tomography are positive; the tracer uptake is moderately more than the liver uptake, at any disease site.
Score 5	`ncit:C99750`	The results of the positron emission tomography are positive; the tracer uptake is markedly increased at any disease site.

PCDC Data Model

Person 1..1

Subject 1..1

ExternalReference 0..*

Study 0..*

Timing 0..*

OffProtocolTherapyStudy 0..*

SurvivalCharacteristic 0..*

FamilyMedicalHistory 0..*

MedicalHistory 0..*

Vital 0..*

FunctionTest 0..*

Lab 0..*

MolecularAnalysis 0..*

Biospecimen 0..*

Immunohistochemistry 0..*

Cytology 0..*

Imaging 0..*

Histology 0..*

Staging 0..*

DiseaseCharacteristic 0..*

MyeloidSarcomaInvolvement 0..*

TumorAssessment 0..*

LesionCharacteristic 0..*

BiopsySurgicalProcedure 0..*

StemCellTransplant 0..*

TransfusionMedicineProcedure 0..*

RadiationTherapy 0..*

TotalDose 0..*

ProtocolTreatmentModifications 0..*

CellularImmunotherapy 0..*

NonProtocolTherapy 0..*

SubjectResponse 0..*

MinimalResidualDisease 0..*

SecondaryMalignantNeoplasm 0..*

AdverseEvent 0..*

GrowingTeratomaSyndrome 0..*

LateEffects 0..*

AbEnum

AdministrationStatusEnum

AdverseEventEnum

AeAttributionEnum

AeExpectedEnum

AeGradeEnum

AeMedInterventionDetailEnum

AeOutcomeEnum

AePathogenConfirmationEnum

AePathogenEnum

AePathogenStatusEnum

AeSystemEnum

AnaplasiaEnum

AnaplasiaExtentEnum

AntineoplasticAgentEnum

AssistedConceptionEnum

BiopsyTypeEnum

BmAnalysisMethodAtResponseEnum

CauseOfDeathDetailEnum

CauseOfDeathEnum

CauseOfDeathRankingEnum

CensorStatusEnum

CimtTypeEnum

CnsDiseaseStatusEnum

ConsortiumEnum

CopyNumberStatusEnum

CourseEnum

CytodifferentiationEnum

CytologySpecTypeEnum

DataContributorIdEnum

DeauvilleScoreEnum

DepthEnum

DetectionMethodEnum

DiamDim1TypeEnum

DiamDim2TypeEnum

DiamDim3TypeEnum

DiseasePhaseEnum

DiseaseSiteEnum

DnaIndexEnum

EExtensionSiteEnum

EnergyTypeEnum

EnrolledStatusEnum

Person `1..1`

Subject `1..1`

ExternalReference `0..*`

Study `0..*`

Timing `0..*`

OffProtocolTherapyStudy `0..*`

SurvivalCharacteristic `0..*`

FamilyMedicalHistory `0..*`

MedicalHistory `0..*`

Vital `0..*`

FunctionTest `0..*`

Lab `0..*`

MolecularAnalysis `0..*`

Biospecimen `0..*`

Immunohistochemistry `0..*`

Cytology `0..*`

Imaging `0..*`

Histology `0..*`

Staging `0..*`

DiseaseCharacteristic `0..*`

MyeloidSarcomaInvolvement `0..*`

TumorAssessment `0..*`

LesionCharacteristic `0..*`

BiopsySurgicalProcedure `0..*`

StemCellTransplant `0..*`

TransfusionMedicineProcedure `0..*`

RadiationTherapy `0..*`

TotalDose `0..*`

ProtocolTreatmentModifications `0..*`

CellularImmunotherapy `0..*`

NonProtocolTherapy `0..*`

SubjectResponse `0..*`

MinimalResidualDisease `0..*`

SecondaryMalignantNeoplasm `0..*`

AdverseEvent `0..*`

GrowingTeratomaSyndrome `0..*`

LateEffects `0..*`

Permissible Value	Meaning	Description
Biopsy	`ncit:C15189`	Patient required removal of tissue or fluid specimen to establish a diagnosis, including biopsy and blood samples.
Bone Marrow Results	`ncit:C190021`	The results of a bone marrow test.
Cerebrospinal Fluid Results	`ncit:C168884`	The results of cerebrospinal fluid laboratory tests.
Clinical Signs or Symptoms	`ncit:C100104`	Objective evidence of disease perceptible to the examiner (sign) and subjective evidence of disease perceived by the subject (symptom).
Imaging	`ncit:C15189`	Patient required removal of tissue or fluid specimen to establish a diagnosis, including biopsy and blood samples.
Tumor Marker	`ncit:C17220`	A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Cranial-Caudal	`ncit:C182395`	A measure of the craniocaudal dimension of the tumor.
Transverse	`ncit:C182199`	A measure of the transaxial dimension of the tumor.
Unknown	`ncit:C17998`	A proper value is applicable but not known.

Permissible Value	Meaning	Description
Initial Diagnosis	`ncit:C156813`	The first diagnosis of the disease.
Progression	`ncit:C17747`	A disease, condition, or injury that is increasing in extent or severity.
Refractory	`ncit:C38014`	In medicine, describes a disease or condition that does not respond to treatment.
Relapse	`ncit:C38155`	The return of a disease after a period of remission.
Relapse/Progression	`ncit:C174991`	Either the return of the disease or the progression of the disease.

Permissible Value	Meaning	Description
Bone Marrow	`ncit:C12431`	The soft tissue that fills the cavities of bones.
Central Nervous System	`ncit:C12438`	The brain and spinal cord.
Testes	`ncit:C12412`	A gonad of a male animal. A gonad produces and releases sperm.
Other	`ncit:C17649`	A proper value is applicable but not known.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
DNA Index </= 1 (Hypodiploid, Diploid)
DNA Index >1 (Hyperdiploid)
Unknown
Not Reported

Permissible Value	Meaning	Description
Bone	`ncit:C12366`	Calcified connective tissue that forms the skeletal components of the body. (NCI)
Chest Wall	`ncit:C62484`	Subdivision of thorax which includes all structures from the skin to the costal pleura. Examples: There is only one chest wall.
Heart	`ncit:C12727`	A hollow muscular organ which receives the blood from the veins and pumps it into the arteries.
Lungs	`ncit:C12468`	A thoracic organ that has variable lobation and is the primary respiratory organ of mammals.
Soft Tissue	`ncit:C12471`	A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.
Other	`ncit:C17649`	A proper value is applicable but not known.

Permissible Value	Meaning	Description
3D Conformal	`ncit:C16035`	A procedure that uses a computer to create a 3-dimensional picture of the tumor. This allows doctors to give the highest possible dose of radiation to the tumor, while sparing the normal tissue as much as possible.
Brachytherapy	`ncit:C15195`	A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.
Electrons
Intensity-Modulated Radiation Therapy	`ncit:C16135`
Photon	`ncit:C88112`	A single unit of electromagnetic radiation, generally considered to be a discrete particle having no mass or charge.
Proton	`ncit:C66897`	A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.
Protons	`ncit:C66897`	A type of external beam radiation therapy using a beam of protons. It has the advantage of precisely localizing the radiation dose on the targeted tissue and avoiding damage to the healthy surrounding tissues.
Other
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Hispanic or Latino	`ncit:C17459`	A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. (NCI)
Not Hispanic or Latino	`ncit:C41222`	A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
AML, NOS	`ncit:C27753`	Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.
M0	`ncit:C8460`	An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)
M1	`ncit:C3249`	An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)
M2	`ncit:C3250`	An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)
M3	`ncit:C3182`	An acute promyelocytic leukemia characterized by the reciprocal balanced translocation t(15;17)(q24.1;q21.2) that results in the fusion of the promyelocytic leukemia (PML) gene and retinoic acid receptor-alpha (RARA) gene. The t(15;17)(q24.1;q21.2) with the resulting PML-RARA fusion gene occurs in over 95% of cases of acute promyelocytic leukemia. The remainder of the cases show variant RARA gene translocations with other genes.
M3 Variant	`ncit:C27757`	Acute promyelocytic leukemia in which the promyelocytes in the peripheral blood have paucity or absence of cytoplasmic granules and characteristic bilobed nuclei.
M4	`ncit:C7463`	An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors. (WHO, 2001)
M4eo	`ncit:C9020`	Acute myelomonocytic leukemia characterized by the presence of abnormal bone marrow eosinophils. It is associated with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22). It has a favorable prognosis.
M5	`ncit:C4861`	A progressive, proliferative disease of blood cells, originating from immature monocytes.
M6	`ncit:C8923`	A progressive, proliferative disease of blood cells, originating from immature erythroid cells.
M7	`ncit:C3170`	A progressive, proliferative disease of blood cells, originating from immature megakaryocytes.
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.

Permissible Value	Meaning	Description
Different-from-Normal	`ncit:C168956`
Leukemia-Associated Immunophenotypes	`ncit:C168812`
Unknown	`ncit:C17998`	A proper value is applicable but not known.
Not Reported	`ncit:C43234`	Not provided or available.